key: cord-0886742-qsz7gtpt
authors: Chen, Yeh; Yang, Wen-Hao; Chen, Hsiao-Fan; Huang, Li-Min; Gao, Jing-Yan; Lin, Cheng-Wen; Wang, Yu-Chuan; Yang, Chia-Shin; Liu, Yi-Liang; Hou, Mei-Hui; Tsai, Chia-Ling; Chou, Yi-Zhen; Huang, Bao-Yue; Hung, Chian-Fang; Hung, Yu-Lin; Wang, Wei-Jan; Su, Wen-Chi; Kumar, Vathan; Wu, Yu-Chieh; Chao, Shih-Wei; Chang, Chih-Shiang; Chen, Jin-Shing; Chiang, Yu-Ping; Cho, Der-Yang; Jeng, Long-Bin; Tsai, Chang-Hai; Hung, Mien-Chie
title: Tafenoquine and its derivatives as inhibitors for the Severe Acute Respiratory Syndrome Coronavirus 2
date: 2022-01-29
journal: J Biol Chem
DOI: 10.1016/j.jbc.2022.101658
sha: 5e81726fdee7c1f478b6dbe9054846b17130942b
doc_id: 886742
cord_uid: qsz7gtpt

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has severely affected human lives around the world as well as the global economy. Therefore, effective treatments against COVID-19 are urgently needed. Here, we screened a library containing Food and Drug Administration (FDA)-approved compounds to identify drugs that could target the SARS-CoV-2 main protease (M(pro)), which is indispensable for viral protein maturation and regard as an important therapeutic target. We identified anti-malarial drug tafenoquine (TFQ), which is approved for radical cure of Plasmodium vivax and malaria prophylaxis, as a top candidate to inhibit M(pro) protease activity. The crystal structure of SARS-CoV-2 M(pro) in complex with TFQ revealed that TFQ noncovalently bound to and reshaped the substrate binding pocket of M(pro) by altering the loop region (residues 139-144) near the catalytic Cys145, which could block the catalysis of its peptide substrates. We also found that TFQ inhibited human transmembrane protease serine 2 (TMPRSS2). Furthermore, one TFQ derivative, compound 7, showed a better therapeutic index than TFQ on TMPRSS2, and may therefore inhibit the infectibility of SARS-CoV-2, including that of several mutant variants. These results suggest new potential strategies to block infection of SARS-CoV-2 and rising variants.

The SARS-CoV-2 was identified in December 2019 as the cause of COVID-19 outbreak [1] [2] [3] . It has since spread rapidly, infected more than 180 million people, and caused more than 3.9 million deaths [4, 5] globally in late June of 2021. While various kinds of vaccines have been available and large number of people have received, and preliminary analyses from the United States and other countries also showed that a COVID-19 vaccination series is effective against SARS-CoV-2 infection [6] [7] [8] . However, only about 22 percents of the world population have received at least one dose of an approved vaccine in late June of 2021 [9] . At the current global vaccination rate, it is estimated to take at least 4.6 years to achieve worldwide herd immunity (70 to 85% of the population having received a two-dose vaccine) against COVID-19. This long-time gap will allow variants of the virus to develop and spread, potentially rendering current vaccines ineffective [9, 10] . Recently, several novel variants of SARS-CoV-2 with various mutations and deletions in the RBD of spike protein have appeared in multiple countries. In the middle of 2020, spike gene analysis of SARS-CoV-2 revealed a mutation on D614G substitution became more common as the pandemic spread [11] . Furthermore, The B.1.1.7 (Alpha) variant which has D614G mutation and N501Y mutation in spike protein was first identified in the United Kingdom in 2020 and spread rapidly [12] . Subsequently, three more variants of concerns are documented including B. 1 (Delta) from India. Except for variants from India, the other two variants harbor N501Y mutation on RBD, which increases binding affinity to ACE2 [13] . In addition, P.1 variant has an escape mutation E484K which is able to escape the host's immune defenses by the neutralizing antibody [14, 15] . The B.1.617 variant became one of the leading variants from India spread to about 40 nations since January 2021 [16] . It carries two important mutations, E484Q and L452R. Residues J o u r n a l P r e -p r o o f 5 452 and 484 could play a role in resistance to antibody neutralization. Both are separately found in many other coronavirus variants, but they have been reported together for the first time in B.1.617 [17, 18] . Another variant from India, B.1.618, has a specific mutation Δ145-146 [19] .

Residues 145 and 146 are as known as antibody binding sites [20] . The B.1.617.2 is a variant of lineage B.1.617 and has most recently become a variant of concern and named as Delta variant on 31 May 2021 by the World Health Organization. Accordingly, Pfizer utilized vaccine (BNT162b2)-induced human sera to neutralize SARS-CoV-2 lineage B.1.1.7 pseudovirus, with slightly reduced activity compared to the original strain [21] . However, the Moderna mRNA-1273 vaccine showed a five-to ten-fold reduction in efficacy against the B.1.351 strain bearing the E484K mutation comparing to pseudovirus bearing the D614G mutation [22] . Therefore, any improvement of vaccine and anti-SARS-CoV-2 drugs are urgently needed in order to combat the COVID-19 pandemic. Currently, several clinical trials have demonstrated that remdesivir [23, 24] and dexamethasone [25] improves the prognosis in patients with SARA-CoV-2 infection. Until now, remdesivir and dexamethasone have been used for patients who are hospitalized with moderate and severe COVID-19 symptoms in most countries [26] . Monoclonal antibodies (bamlanivimab and etesevimab) are another option of therapeutic agents only for the nonhospitalized patients with mild-to-moderate COVID-19 symptoms [27] . However, the efficacy of remdesivir is limited [23, 28, 29] and dexamethasone is an anti-inflammatory drug which does not directly inhibit virus replication. Hence, we need to continue to rapidly develop effective drugs, especially using the screening strategies for anti-SARS-CoV-2 therapeutics. The Food and Drug Administration (FDA)-approved drugs have undergone rigorous evaluations for safety, and it would be an advantage to screen compound library containing FDA-approved drugs as they can be used quickly applied for treating patients.

The SARS-CoV-2 genome shares about 82 % identity with the SARS coronavirus and contains approximately 30,000 nucleotides that are transcribed into 13-15 open reading frames (Orfs) [30] .

Among them, Orf1a and Orf1ab are translated into two polyproteins which are then cleaved by the M pro , yielding a number of protein products required for viral replication and transcription [31] [32] [33] [34] .

Another critical cell surface protease for mediating virus entry into host cells is TMPRSS2 which trigger cell membrane fusion and uptake of SARS-CoV-2 [35] . Because M pro and TMPRSS2 which digest their substrates at each specific polypeptide sequences are necessary for viral replication and infection respectively, these two proteases are considered as ideal targets for drug design. To this end, we firstly identified antiviral compounds from a library containing FDAapproved drugs which can bind to M pro and inhibit its enzymatic activity through a well-established fluorescence resonance energy transfer (FRET)-based high-throughput drug screening platform.

Here, we found that an US FDA-approved drug tafenoquine (TFQ) not only represses M pro protease activity through inducing its conformational change, but also targets the cellular protease TMPRSS2 to display a dual-function against SARS-CoV-2 activity. In addition, through medicine chemistry approaches, we synthesized 14 derivatives of TFQ and based on therapeutic index, therapeutic efficacy/toxicity, we identified one compound, compound 7 as a safer therapeutic agent than parental TFQ. Importantly, both TFQ and compound 7 suppressed viral infection including several variants through viral pseudoparticle (Vpp) assay.

To rapidly identify potential FDA-approved drugs targeting SARS-CoV-2 M pro , we utilized an established fluorescence resonance energy transfer (FRET) assay to screen 1836 compounds from FDA-Approved Drug Library (MedChemExpress, Cat. No.: HY-L022P) [36] . Among the identified positive candidates, TFQ exhibited the most significant inhibitory effect against SARS-CoV-2 M pro ( Fig. 1a and Table S1 ). The half-maximal inhibitory concentration (IC50) of TFQ against SARS-CoV-2 M pro is 31.8 μM (Fig. 1b) . TFQ (brand name Krintafel/Kozenis in U.S./Australia, owned and developed by GlaxoSmithKline) is an 8-aminoquinoline anti-malarial drug that was approved by the U.S. FDA in July 2018 and the Australian Therapeutic Goods Administration (TGA) in September 2018 for the radical cure of Plasmodium vivax [37] [38] [39] , a parasite that causes malaria. In addition, TFQ (brand name Arakoda/Kodatef in U.S./Australia, owned by 60 Degrees Pharmaceuticals) was later approved by the FDA and the TGA for malaria prophylaxis [39, 40] . However, the molecular target of TFQ is still unknown. Here, we showed that TFQ directly inhibited SARS-CoV-2 M pro in vitro. Another quinoline-based drug, Hydroxychloroquine (HCQ), a 4-aminoquinoline derivative, has shown to be effective in inhibiting SARS-CoV-2 infection in vitro [41] . However, using HCQ for prevention or treatment of severe COVID-19 patients have shown no benefits or have severe side effects [42] [43] [44] . To further characterize TFQ, we compared the inhibitory effects of TFQ and HCQ by using differential scanning fluorimetry (DSF), which is a powerful tool in early drug discovery with the basic principle that drugs which bind to the therapeutic protein target will change its thermal stability [45, 46] . The result showed that TFQ caused thermal shifts in the melting temperature (Tm) of SARS-CoV-2 M pro in a dose-dependent manner (Fig. 1c) . In contrast, HCQ had no J o u r n a l P r e -p r o o f influence on the thermal stability of SARS-CoV-2 M pro (Fig. 1d) , supporting that TFQ may bind to M pro and serve as a candidate to inhibit SARS-CoV-2 M pro .

To further validate the binding and inhibitory effects of TFQ on SARS-CoV-2 M pro , various biophysical methods were utilized to assess the conformational changes of SARS-CoV-2 M pro .

Analytical ultracentrifugation studies revealed identical sedimentation coefficient at various concentrations of TFQ, suggesting that the overall quaternary structure of SARS-CoV-2 M pro remain unchanged in the presence of TFQ (Fig. 2a) . Results from circular dichroism (CD) spectroscopy exhibited an increase in the far-UV signals (molar ellipticity at 222 nm) with increasing concentrations of TFQ, indicating that the total helical content of SARS-CoV-2 M pro decreased upon TFQ binding ( Fig. 2b and Fig. S1 ). In addition, the relative activity of SARS-CoV-2 M pro decreased with increasing concentrations of TFQ (Fig. 2b) , supporting the notion that total helical content of SARS-CoV-2 M pro correlates with relative SARS-CoV-2 M pro activity. To further evaluate the conformational changes of SARS-CoV-2 M pro , we performed a limited proteolysis assay by trypsin digestion [47] . The cleavage pattern, unexpectedly, indicated a greater degree of protection of SARS-CoV-2 M pro from trypsin digestion at higher concentrations of TFQ, which was independent of any effect of TFQ on trypsin activity ( Fig. 2c and Fig. S2 ). In contrast, HCQ did not reduce the cleavage of SARS-CoV-2 M pro by trypsin digestion (Fig. 2c) . These findings suggest that TFQ binding not only reduces the helical content but also induces local conformational changes in SARS-CoV-2 M pro , resulting in resistance to trypsin digestion.

To investigate the inhibitory effect of TFQ on SARS-CoV-2 M pro , we established a cocrystallization structure of TFQ-M pro complex (Table S2 ). The structure revealed that TFQ noncovalently binds to the active site of SARS-CoV-2 M pro with a unique binding pattern that is distinctly different from the known covalent peptidomimetic inhibitors ( Fig. 3a and Fig. S3a ) [48] .

The hydrophobic quinoline core of TFQ locates near the catalytic dyads of SARS-CoV-2 M pro and forms a hydrogen bond with the side-chain of H41 on SARS-CoV-2 M pro , blocking the access of substrates into the active site (Fig. 3a) . The pentan-1,4-diamine moiety of TFQ buries deeply into the S2 subsite, interacting with residues T25, L27, C44, T45, S46, M49 and Q189 of SARS-CoV-In addition to the therapeutic importance of SARS-CoV-2 M pro , TMPRSS2 is a host protease on cell membrane to facilitate SARS-CoV-2 entry into host cells. The recent study indicated that the rapid transmissibility of B.1.617 variant from India could attributed to its increased ability to enter human intestinal and lung cell lines and that specific TMPRSS2 inhibitor is effective against B.1.617 variant [49] . Interestingly, we also observed TFQ to inhibit TMPRSS2 protease activity in a dose-dependent manner (Fig. S4) , suggesting TFQ could block SARS-CoV-2 by inhibiting enzymatic activities of both SARS-CoV-2 M pro and host TMPRSS2.

Next, we examined the antiviral efficacy of TFQ on the viral production and infection rates of SARS-CoV-2. Vero E6 cells, which are kidney epithelial cells isolated from an African green monkey and commonly used to produce SARS-CoV-2 [36, 50] were infected with SARS-CoV-2 [51, 52] . Vero E6 cells are susceptible to SARS-CoV-2 infection, which induces CPE [53] . We observed a significant decrease in SARS-CoV-2-induced CPE in Vero E6 cells treated with 5 μM TFQ treatment compared with the DMSO treatment group (Fig. 4d) , indicating that TFQ mitigates cell damages caused by SARS-CoV-2. Therefore, the data in Figure 4b observed on day 3 showed that there is no significant difference of viral RNA between DMSO-treated and TFQ (2.5 μM)-treated groups because the former lacked sufficient number of surviving host cells for virus production.

Collectively, these data demonstrated that TFQ reduced SARS-CoV-2 production in the host cells.

To further investigate whether the inhibition effect of TFQ on SARS-CoV-2 production is mediated through M pro , we established two stable HEK-293T cell lines expressing M pro -CFP-YFP or M pro -GFP-RFP fusion proteins. The M pro cleavage site is placed between the CFP-YFP or GFP-RFP gene to evaluate the SARS-CoV-2 M pro activity using fluorescence detection. SARS-CoV-2 M pro fusion protein is accommodated with CFP-YFP or GFP-RFP by the F2A enhancing fusion. The results showed that SARS-CoV-2 M pro has an activity that cleaved GFP and RFP at the cleavage site and separated GFP-RFP with the single fluorescent expression in the cell under microscopy determination (Fig. S5 ). The endogenous fluorescence is reversed and combined significantly with the M pro activity inhibition by TFQ treatment (50 and 100 μM) in the HEK-293T cells (Fig. S5 ).

The inhibition of M pro activity by TFQ was also confirmed by FRET detection in the HEK-293T cell lysates (Fig. S6 ). In the presence of SARS-CoV-2 M pro activity, FRET detection was reduced.

Addition of 100 μM TFQ consistently lower SARS-CoV-2 M pro activity, resulting in a two-fold J o u r n a l P r e -p r o o f increase in FRET percentage (Fig. S6 ). Taken together, these in vivo data suggested that despite at high-dose, TFQ inhibited SARS-CoV-2 production through M pro , which is also consistent with the result of in vitro M pro activity analysis ( Figure 1b ).

TFQ blocked SARS-CoV-2 viral infection (Fig. 4) , at least in part, by inhibiting the enzymatic activity of viral M pro (Fig. 1 ) and host TMPRSS2 proteases (Fig. S4 ). As shown in Fig. S7c -d, TFQ was equipotent in inhibiting both enzyme activities. TFQ exhibits CPE at 5 μM ( Fig. 4) , thus the therapeutic window may be limited to develop into a clinically useful drug. We turned our attention to the use of TFQ as a base compound to develop specific, noncytotoxic inhibitors as therapeutic intervention for COVID-19 [54, 55] . Based on the structural information shown in Fig. 3 , we employed two different strategies to conduct structural modifications of TFQ to develop M pro and TMPRSS2 inhibitors, which is delineated as follows. Our initial effort focused on the direct derivatization of TFQ by substituting or replacing the aniline amino moiety and/or the terminal-NH2 of the alkyl side chain with different functionalities, leading to compounds 1 -6 ( Fig. S7b ).

However, these compounds with the exception of compound 3 showed substantially reduced inhibitory activities toward both proteases ( Fig. S7b -d). In compound 3, the N-monomethylation at the terminal-NH2 retained the TMPRSS2 inhibitory activity, but gave rise to a partial loss of the M pro inhibitory activity which might be attributable to steric hindrance imposed by the N-CH3 substitution for ligand interactions with the H41 and C44 residues of M pro (Fig. 3) . This premise was corroborated by losses of the M pro inhibitor activity to a greater extent in compounds 2 and 4 by adding an additional N-methyl function to either the terminal-NH2 and the aniline-NH, respectively (Fig. S5c) . Interestingly, compounds 2 and 4 also showed a complete or significant J o u r n a l P r e -p r o o f 13 loss of the TMPRSS2 inhibitory activity (Fig. S7d) , suggesting the importance of the terminal-NH2 in the mode of ligand binding with TMPRSS2. It is interesting that an additional N-methyl function at either the terminal-NH2 (compound 2) or the aniline-NH (compound 4) resulted in a complete loss of the TMPRSS2 inhibitory activity (Fig. S7b-d) . Replacement of the terminal-NH2 moiety of TFQ with a guanidino (compound 5) or thiourea (compound 6) group, which was aimed at enhancing potential hydrogen bonding with the H41 and C44 residues of M pro (Fig. 3 ), led to a complete loss of both inhibitory activities presumably due to steric hindrance ( Fig. S5b-d) .

Together, these data suggest a subtle structure-activity relationship, which prompted us to take an alternative fragment-based strategy by selecting compound 7, a key intermediate in TFQ synthesis, as a starting point for modifications (Fig. S8a) . We coupled compound 7 with terminal NH2containing alkyl or acyl side chains with varying lengths (Series I, compounds 8 -10) or with different amino acids [Series II, including L-asparagine, L-glutamine, L-lysine, and L-ornithine, compounds 11 -14, respectively) (Fig. S8a) . We rationalized that these changes might allow a better differentiation of the binding pocket of TMPRSS2 versus M pro by these small-molecule compounds. It is noteworthy that among these eight derivatives (7 -14), compound 7 exhibited a nearly effective TMPRSS2 inhibitory activity relative to TFQ, while deficient in M pro inhibition ( Fig. S8b, c) . Moreover, compounds 8 and 13 also showed discriminative inhibitory activities between TMPRSS2 and M pro in favor of the former (Fig. S8b, c) . This loss of M pro inhibitory activity in compounds 8 and 13 underlies the stringent requirement of the length of the aminoalkyl side chain in directing the interaction of the terminal-NH2 with the H41 and C44 residues of M pro , as depicted in Fig. 3 .

J o u r n a l P r e -p r o o f Since a crucial issue of TFQ is its narrow safety margin for clinical treatment, it is important to determine the cytotoxicity of these TFQ-derived compounds. After the cytotoxicity screening by using MTT assay in the Vero E6 and Calu3 cells, we found that one of the TFQ-derived compounds, compound 7, had the highest drug safety in both cell lines (Fig. 5a, b) . To further measure the CC50 (50% cytotoxic concentration) of compound 7 compared with TFQ, the results showed that compound 7 had an CC50 value 10-fold higher than TFQ in both Vero E6 and Calu3 cell lines (Fig. 5c, d) . As the aminoalkyl side chain of TFQ was truncated in compound 7, these results suggested the role of this substructure in contributing not only to the M pro inhibitory activity but also to cytotoxicity of TFQ (Fig. 5e ).

To further examine the potential activity of compound 7 in SARS-CoV-2 infection, SARS-CoV-2 pseudovirus assay was employed in human bronchial epithelial Calu-3 and monkey kidney epithelial Vero E6 cells, respectively. Recent reports indicated that there are two major entry pathways of SARS-CoV-2, either through the ACE2-endosomal pathway or via TMPRSS2 at the cell surface [56] . Vero E6 cells, a common cell line for the SARS-CoV-2 study, have high ACE2 expression levels but with low TMPRSS2 expression. This finding suggests a link between SARS-CoV-2 entry and the ACE2-endosomal pathway in Vero E6 cells. On the other hand, as Calu3 cells express a high level of TMPRSS2, SARS-CoV-2 entry into Calu3 cells might be TMPRSS2dependent. In light of the high potency of compound 7 in TMPRSS2 inhibition, we further established a TMPRSS2-expressing system in both cell lines (Fig. 6a) . These cells were pre-treated with HCQ, TFQ, or compound 7 for 1 hour, and then infected with the SARS-CoV-2 viral pseudoparticle (Vpp). After 24 hours of incubation, infection efficiency was measured according to luciferase activities. As HCQ is an inhibitor of the endosomal pathway, published reports showed that it does not block SARS-CoV-2 infection in the TMPRSS2-expressing cells [57] . Indeed, J o u r n a l P r e -p r o o f results from three independent experiments showed that HCQ only blocked infection of SARS-CoV-2 viral pseudo-particle in wild-type Vero E6 cells, but not in TMPRSS2-overexpressing cells (Fig. 6b) . In contrast, both TFQ and compound 7 at high doses were more effective in inhibiting viral infection in TMPRSS2-overexpressing cells than that in the parental cells (Fig. 6b, c) . These results suggested that TFQ and compound 7 could inhibit SARS-CoV-2 viral pseudo-particles likely through inhibiting TMPRSS2 activity. Indeed, the cell-based TMPRSS2 enzymatic assay revealed that both TFQ and compound 7 blocked protease activity of TMPRSS2 through competitive inhibition mode and the inhibition constant Ki of them were determined to be 10.18 and 16.79 μM, respectively (Fig. S9) . Furthermore, compound 7 showed a much higher selectivity index (SI) than TFQ (Fig. 6d) . Our finding suggested that the compound 7 may be a promising (Fig. 6e, f) . The results indicated that both the EC50 and SI of TFQ or compound 7 were similar between wild type and each variant (Fig. 6g, h) . In conclusion, we found that compound 7 could not only repress infectivity of wild-type SARS-CoV-2, but also different variants of mutant viral pseudo-particles.

Drug repurposing is an efficient way to accelerate the development of therapies for COVID-19. Interestingly, several non-covalent, non-peptidomimetic small-molecule compounds were also reported to inhibit SARS-CoV-2 M pro [61] [62] [63] . For example, baicalein, ML188 and MUT056399 can bind to the active site and block access of the substrates to the catalytic dyad [61] [62] [63] . In addition, pelitinib, ifenprodil, tofogliflozin and AT7519 were discovered to bind to two newly identified allosteric sites of SARS-CoV-2 M pro , affecting its dimerization and thus the catalytic ability [62] . In general, non-covalent inhibitors has the advantage of less off-target toxicity over J o u r n a l P r e -p r o o f covalent inhibitors [64] . Moreover, covalent, peptidomimetic inhibitors are prone to proteolytic degradation, which limits their therapeutic application [65] . For instance, the N3 inhibitor blocked SARS-CoV-2 at a concentration of 10 μM in cell-based assay [48] whereas TFQ exhibited strong antiviral effect at a concentration of 5 μM in SARS-CoV-2 infected Vero E6 cells (Fig. 4) .

TFQ is approved for prophylaxis and treatment of malaria in the U.S. and Australia [40, 66] . As a preventive measure, a dose of 200 mg TFQ is recommended for three days prior to traveling and 200 mg per week until one week after return. For radical cure, a single dose of 300 mg TFQ is recommended (https://wwwnc.cdc.gov/travel/news-announcements/tafenoquine-malariaprophylaxis-and-treatment). Those above dose recommendations for malaria prophylaxis suggested that TFQ at higher doses may be suitable for human consumption. As shown in Fig. 4 , the therapeutic window of TFQ in cell culture may be limited, we thereby turn to develop potential drug candidate targeting both SARS-CoV-2 M pro and TMPRSS2 with higher safety using TFQ as scaffold. Although the TFQ derived compound 1-14 did not exhibit significant inhibitory effect on SARS-CoV-2 M pro , it has provided useful structural and functional relationship. For example, the reduced inhibitory effects of compound 2 and 3 probably resulted from the mono-methylation (compound 3) and di-methylation (compound 2) of the terminal-NH2 group of the aminoalkyl side chain of TFQ that breaks the formation of hydrogen bonding to H41 and C44 according to our solved M pro -TFQ structure ( Fig. 3a and Fig. S5c) . Furthermore, the inverse relationship of the length of the aminoalkyl side chain of TFQ (Compound 7-10, Fig. S6b) and their corresponding inhibitory effects suggested the importance of the hydrophobic interaction between this aminoalkyl side chain and the substrate-binding pocket of SARS-CoV-2 M pro as mentioned above (Fig. 3a, b) .

Despite the absence of complex structure of human TMPRSS2 with TFQ, we have identified TFQderived compound 7 as a novel, noncytotoxic inhibitor against TMPRSS2 in enzyme activity assay. 

The viability of cells after 24 hours treatment was determined using the standard MTT [3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay. All the treatments were done using 5×10 3 cells/well in 96 wells plate. The purple formazan crystals were dissolved in DMSO (100 µL/well) and the absorbance was recorded on a microplate reader at a wavelength of 570 nm. The CC50 values (50% cytotoxic concentration) was defined as the compound's concentration (µM) required for the reduction of cell viability by 50% and were calculated by using GraphPad PRISM software.

Cell lysates were collected by RIPA buffer plus protease inhibitors. The concentration of total protein was measured by Bradford protein assay. Protein was denatured at 95℃ for 5 minutes, and loaded into SDS-PAGE to run. The SDS-PAGE was transferred to a PVDF membrane, and the membrane was blocked with 5% milk. After blocking, the membrane was immune-stained with immediately by the GloMax Navigator System (Promega) and normalized with cell viability first, then the control group was set as 100% and the relative infection efficiencies were calculated.

The cloning, expression and purification of SARS-CoV-2 M pro and its fluorescent protein substrate were described previously [36] . The calculated initial velocity with each compound was normalized to DMSO control. The IC50

was calculated by plotting the initial velocity against various concentrations of TFQ by use of a dose-response curve in Prism 8 software.

For enzyme activity assay of human TMPRSS2, tested compounds were first incubated with TMPRSS2 protein at room temperature, the fluorescent protein substrate was then added to start the reaction. The fluorescence signal was detected with excitation wavelength of 506 nm and emission wavelength of 536 nm.

Protein thermal shift assay using differential scanning fluorimetry Differential scanning fluorimetry (DSF) assays were conducted as previously described (Lo, et 

The protein sample was preincubated with or without various concentrations of TFQ or HCQ (30- For immunofluorescence assay, 1 x 10 5 mock and stable clone M pro -GFP-RFP expression cells per well were seeded on coverslips, which were placed in 24-well plate, incubated at 37 ℃, 5 % CO2

overnight. The stable cells then were treated with 100 μM TFQ and 50 μM TFQ for 8 hours.

Following the immunofluorescence assay, cells were fixed with 4 % formalin for 30 minutes and were stained with DAPI, 20 minutes. Cells then were washed with PBS 3 times, for 5 minutes each washing. The mount solution was used to mount cells overnight at room temperature. This assay is performed in the dark.

VeroE6-TMPRSS2 cells were seeded in a black, 96-well plate (5,000 cells/well). Next day, the After 24 hours of infection, the infection efficiency rate was measured by luciferase activities.

Error bars represent the standard deviation of the means. c The EC50 of TFQ and compound 7 was determined by GraphPad PRISM software, expressed as mean±SD. d The selectivity index (SI) of TFQ and compound 7 were measured by mean CC50/ mean EC50. e-f VeroE6 cells with

A Novel Coronavirus from Patients with Pneumonia in China

A pneumonia outbreak associated with a new coronavirus of probable bat origin

A new coronavirus associated with human respiratory disease in China

An interactive web-based dashboard to track COVID-19 in real time

World Health Organization. Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update

FDA-authorized COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine

A global database of COVID-19 vaccinations

From Vaccine Nationalism to Vaccine Equity -Finding a Path Forward

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose

SARS-CoV-2 RBD <em>in vitro</em> evolution follows contagious mutation spread, yet generates an able infection inhibitor

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

Coronavirus variants are spreading in India -what scientists know so far

Possible link between higher transmissibility of B.1.617 and B.1.1.7 variants of SARS-CoV-2 and increased structural stability of its spike protein and hACE2 affinity

Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra

The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccine-elicited and Therapeutic Monoclonal Antibodies

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial

Remdesivir in adults with severe COVID-19: a randomised, doubleblind, placebo-controlled, multicentre trial

Dexamethasone in Hospitalized Patients with Covid-19

COVID-19 Treatment Guidelines: Do They Really Reflect Best Medical Practices to Manage the Pandemic? Infect Dis Rep

Neutralizing monoclonal antibodies for treatment of COVID-19

Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results

Remdesivir and systemic corticosteroids for the treatment of COVID-19: A Bayesian re-analysis

Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach

An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy

Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs

Conservation of substrate specificities among coronavirus main proteases

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Structural basis of SARS-CoV-2 main protease inhibition by a broadspectrum anti-coronaviral drug

Killing the hypnozoite--drug discovery approaches to prevent relapse in Plasmodium vivax. Pathog Glob Health

Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date

Clinical utility of tafenoquine in the prevention of relapse of Plasmodium vivax malaria: a review on the mode of action and emerging trial data

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019

A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19

Hydroxychloroquine treatment does not reduce COVID-19 mortality; underdosing to the wrong patients? The Lancet Rheumatology

High-density miniaturized thermal shift assays as a general strategy for drug discovery

Disrupting the Constitutive, Homodimeric Protein-Protein Interface in CK2β Using a Biophysical Fragment-Based Approach

Limited proteolysis as a tool to probe the tertiary conformation of dysferlin and structural consequences of patient missense variant L344P

Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors

SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination

Coronaviridae and SARS-associated coronavirus strain HSR1

SARS coronavirus induces apoptosis in Vero E6 cells

Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States. Emerg Infect Dis

Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies

Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities

SARS-CoV-2 entry in host cells-multiple targets for treatment and prevention

Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2

The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor

A structural view of the inactivation of the SARS coronavirus main proteinase by benzotriazole esters

A novel conformational state for SARS-CoV-2 main protease

Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188. Viruses

X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease

Discovery of baicalin and baicalein as novel, natural product inhibitors of SARS-CoV-2 3CL protease in vitro

Covalent Versus Non-covalent Enzyme Inhibition: Which Route Should We Take? A Justification of the Good and Bad from Molecular Modelling Perspective

Differential stability of therapeutic peptides with different proteolytic cleavage sites in blood, plasma and serum

Guidance for Using Tafenoquine for Prevention and Antirelapse Therapy for Malaria -United States

The emergence of new strains of SARS-CoV-2. What does it mean for COVID-19 vaccines?

Acknowledgments: We would like to thank Ms. Yi-Jen Liau at National Taiwan University for technical assistance of SARS-CoV-2 preparation, SCI Pharmtech Inc. for providing HCQ, and Dr. Jeng Cheng for professional editing and proofreading. Funding: This research was supported in part by the following: The Ministry of Science and Technology, Taiwan (MOST108-2311-B-241-001

); the "Drug Development Center, China Medical University" from the Featured Areas Research Center Program within the Framework of the Higher Education Sprout Project by the Ministry of Education (MOE)

Formal analysis

Writing -Review & Editing, Supervision